JP2018538270A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538270A5
JP2018538270A5 JP2018526218A JP2018526218A JP2018538270A5 JP 2018538270 A5 JP2018538270 A5 JP 2018538270A5 JP 2018526218 A JP2018526218 A JP 2018526218A JP 2018526218 A JP2018526218 A JP 2018526218A JP 2018538270 A5 JP2018538270 A5 JP 2018538270A5
Authority
JP
Japan
Prior art keywords
rhc1
inh
composition
recombinant
purified recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018526218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538270A (ja
JP7189767B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/062906 external-priority patent/WO2017087882A1/en
Publication of JP2018538270A publication Critical patent/JP2018538270A/ja
Publication of JP2018538270A5 publication Critical patent/JP2018538270A5/ja
Priority to JP2021105576A priority Critical patent/JP2021155438A/ja
Application granted granted Critical
Publication of JP7189767B2 publication Critical patent/JP7189767B2/ja
Priority to JP2023070030A priority patent/JP7562747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018526218A 2015-11-19 2016-11-18 組換えヒトｃ１エステラーゼインヒビター及びその使用 Active JP7189767B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021105576A JP2021155438A (ja) 2015-11-19 2021-06-25 組換えヒトｃ１エステラーゼインヒビター及びその使用
JP2023070030A JP7562747B2 (ja) 2015-11-19 2023-04-21 組換えヒトｃ１エステラーゼインヒビター及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257711P 2015-11-19 2015-11-19
US62/257,711 2015-11-19
PCT/US2016/062906 WO2017087882A1 (en) 2015-11-19 2016-11-18 Recombinant human c1 esterase inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021105576A Division JP2021155438A (ja) 2015-11-19 2021-06-25 組換えヒトｃ１エステラーゼインヒビター及びその使用

Publications (3)

Publication Number Publication Date
JP2018538270A JP2018538270A (ja) 2018-12-27
JP2018538270A5 true JP2018538270A5 (https=) 2020-01-09
JP7189767B2 JP7189767B2 (ja) 2022-12-14

Family

ID=57543175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018526218A Active JP7189767B2 (ja) 2015-11-19 2016-11-18 組換えヒトｃ１エステラーゼインヒビター及びその使用
JP2021105576A Pending JP2021155438A (ja) 2015-11-19 2021-06-25 組換えヒトｃ１エステラーゼインヒビター及びその使用
JP2023070030A Active JP7562747B2 (ja) 2015-11-19 2023-04-21 組換えヒトｃ１エステラーゼインヒビター及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021105576A Pending JP2021155438A (ja) 2015-11-19 2021-06-25 組換えヒトｃ１エステラーゼインヒビター及びその使用
JP2023070030A Active JP7562747B2 (ja) 2015-11-19 2023-04-21 組換えヒトｃ１エステラーゼインヒビター及びその使用

Country Status (9)

Country Link
US (1) US12209116B2 (https=)
EP (1) EP3377093B1 (https=)
JP (3) JP7189767B2 (https=)
CN (1) CN108463243B (https=)
BR (1) BR112018010160A8 (https=)
CA (1) CA3005906A1 (https=)
ES (1) ES2927271T3 (https=)
MA (1) MA43270A (https=)
WO (1) WO2017087882A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
JP7470119B2 (ja) 2018-08-24 2024-04-17 シーエスエル ベーリング ジーン セラピー インコーポレイテッド 無血清培地におけるベクター産生
US20210380636A1 (en) * 2018-10-17 2021-12-09 Csl Behring Gmbh Process for purifying c1-inh
EP3994165A1 (en) * 2019-07-04 2022-05-11 CSL Behring GmbH Process for purifying c1-inh
SE546553C2 (en) * 2019-10-08 2024-11-26 Hubert Schwarz A method to feed component in perfusion culture
WO2021081280A1 (en) * 2019-10-23 2021-04-29 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
US20230323422A1 (en) * 2020-08-14 2023-10-12 Bristol-Myers Squibb Company Method of making protein
BE1029146B1 (fr) * 2021-02-26 2022-09-26 Xpress Biologics Procede de purification d'une proteine d'interet

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP3543106B2 (ja) * 1999-07-21 2004-07-14 大阪大学長 膜結合型ｃ１インアクチベーター
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
EP1543106B1 (en) 2002-07-15 2007-04-11 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
WO2004034971A2 (en) * 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
PL2380587T3 (pl) * 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
DK3438131T3 (da) 2006-02-10 2022-04-11 Life Technologies Corp Oligosaccharidmodifikation og mærkning af proteiner
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2930245B1 (en) 2007-10-12 2017-11-22 Sigma-Aldrich Co. LLC Cell line and methods for improved glycoprotein sialylation
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
WO2009143493A2 (en) * 2008-05-22 2009-11-26 Attagene Inc. MODULATORS OF TNFα-DEPENDENT SIGNALING PATHWAYS AND USES THEREOF
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
JP5907540B2 (ja) 2011-02-10 2016-04-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 綿を含む固定相を用いるクロマトグラフィーによりグリカン及び／又は複合糖質を精製するための方法
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
CA2867593A1 (en) * 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
EP3110508A4 (en) * 2014-02-28 2017-11-08 Santarus Inc. Treatment of hereditary angioedema with c1 inhibitor
ES2736127T3 (es) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same

Similar Documents

Publication Publication Date Title
JP2018538270A5 (https=)
US10626431B2 (en) Method for improved isolation of recombinantly produced proteins
JP7142021B2 (ja) 糖タンパク質製造プロセス
JP6474798B2 (ja) 方法
US20240025950A1 (en) Method of purification of recombinantly-produced rsv proteins in trimeric form
WO2014110440A1 (en) Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures
WO2012049245A1 (en) Method for purification of complement factor h
CN116670270A (zh) 控制碱性磷酸酶制造期间的总唾液酸含量(tsac)的方法
JP2015518882A (ja) 高グリコシル化された持続型ヒト成長ホルモンタンパク質及びその製造方法
TW201723174A (zh) 重組蛋白質的製造方法
CN106414719B (zh) 生物反应器中重组von Willebrand因子的改进生产
AU2013202965B2 (en) Improved method for producing factor h from a plasma precipitation fraction
JP5274529B2 (ja) 組換えアンチトロンビンおよびその製造方法
WO2007136327A1 (en) A method of producing igg
JP5722314B2 (ja) 高純度可溶性トロンボモジュリン及びその製造方法
CN102858978B (zh) 高纯度可溶性血栓调节蛋白及其制造方法
HK40007078A (en) Method for isolation of recombinantly produced proteins
HK1232914A1 (en) Improved production of recombinant von willebrand factor in a bioreactor
HK1232914B (en) Improved production of recombinant von willebrand factor in a bioreactor